Mehta T, Malinovsky Y, Abnet CC, Albert PS. Using group testing in a two-phase epidemiologic design to identify the effects of a large number of antibody reactions on disease risk.
BMC Med Res Methodol 2022;
22:324. [PMID:
36526967 PMCID:
PMC9756457 DOI:
10.1186/s12874-022-01798-0]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Accepted: 11/21/2022] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND
The role of immunological responses to exposed bacteria on disease incidence is increasingly under investigation. With many bacterial species, and many potential antibody reactions to a particular species, the large number of assays required for this type of discovery can make it prohibitively expensive. We propose a two-phase group testing design to more efficiently screen numerous antibody effects in a case-control setting.
METHODS
Phase 1 uses group testing to select antibodies that are differentially expressed between cases and controls. The selected antibodies go on to Phase 2 individual testing.
RESULTS
We evaluate the two-phase group testing design through simulations and example data and find that it substantially reduces the number of assays required relative to standard case-control and group testing designs, while maintaining similar statistical properties.
CONCLUSION
The proposed two-phase group testing design can dramatically reduce the number of assays required, while providing comparable results to a case-control design.
Collapse